IndiGo to raise up to Rs 4,000 crore via QIP; stock recovers from March low
IndiGo to raise up to Rs 4,000 crore via QIP; stock recovers from March low

IndiGo to raise up to Rs 4,000 crore via QIP; stock recovers from March low

DSIJ Intelligence Article rating: 4.8

InterGlobe Aviation, which runs one of India’s most popular airlines IndiGo, announced that the company’s board of directors has approved fundraising of up to Rs 4,000 crore through the issuance of equity shares by way of a qualified institutional placement (QIP).

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 4.7

The market opened in green on August 11, 2020, overall volumes in futures & options currently stand at 1,48,78,121 crore contracts with a turnover of Rs. 10,49,122.07 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 4.5

The market opened in green on August 11, 2020, overall volumes in futures & options currently stand at 1,48,78,121 crore contracts with a turnover of Rs. 10,49,122.07 crore.

Dr Reddy's Laboratories launch generic version of Ciprodex
Dr Reddy's Laboratories launch generic version of Ciprodex

Dr Reddy's Laboratories launch generic version of Ciprodex

Amir Shaikh Article rating: 4.5

Dr Reddy's Laboratories informed the bourses that along with its US subsidiary, it has launched Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex

Gufic Lifesciences signs pact with Hetero Labs for Remdesivir lyophilised powder
Gufic Lifesciences signs pact with Hetero Labs for Remdesivir lyophilised powder

Gufic Lifesciences signs pact with Hetero Labs for Remdesivir lyophilised powder

Apurva Joshi Article rating: 3.4

Gufic Lifesciences Private Limited (GLPL) has entered into a loan license agreement with Hetero Labs Limited to manufacture and supply Remdesivir lyophilised powder for injection (100 mg/vial) on loan license basis to Hetero for its sale in various countries, including India.

Cupid gets USFDA nod to market male contraceptive variants in US
Cupid gets USFDA nod to market male contraceptive variants in US

Cupid gets USFDA nod to market male contraceptive variants in US

Nidhi Jani Article rating: 3.9

The company has received USFDA nod for the additional four variants to market them in the United States. Earlier, the company had received USFDA approval for one variant of male contraceptives.

Bulls likely to break shackle on market greenery
Bulls likely to break shackle on market greenery

Bulls likely to break shackle on market greenery

DSIJ Intelligence-3 Article rating: 5.0

Tracking positive global cues with indications of Nifty to open with gains of 43 points at 11, 362 levels, the Indian markets are likely to open in green. With index likely to open near its resistance level as on the upside, the zone of 11,340-11,380 continues to be a strong hurdle for the bulls.

RSS
First28182819282028212823282528262827Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR